Loring Wolcott & Coolidge Fiduciary Advisors LLP Moderna, Inc. Transaction History
Loring Wolcott & Coolidge Fiduciary Advisors LLP
- $10.5 Billion
- Q2 2024
A detailed history of Loring Wolcott & Coolidge Fiduciary Advisors LLP transactions in Moderna, Inc. stock. As of the latest transaction made, Loring Wolcott & Coolidge Fiduciary Advisors LLP holds 490 shares of MRNA stock, worth $59,833. This represents 0.0% of its overall portfolio holdings.
Number of Shares
490
Previous 490
-0.0%
Holding current value
$59,833
Previous $52,000
11.54%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding MRNA
# of Institutions
1,054Shares Held
244MCall Options Held
12.1MPut Options Held
9.35M-
Baillie Gifford & CO43.4MShares$5.31 Billion4.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA39MShares$4.77 Billion0.08% of portfolio
-
Black Rock Inc. New York, NY25.4MShares$3.1 Billion0.06% of portfolio
-
State Street Corp Boston, MA14.5MShares$1.76 Billion0.07% of portfolio
-
Flagship Pioneering Inc. Cambridge, MA9.67MShares$1.18 Billion67.87% of portfolio
About Moderna, Inc.
- Ticker MRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 391,200,000
- Market Cap $47.8B
- Description
- Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...